Biotechnology Value Fund L P Reported increased Interest in Vitae Pharmaceuticals Inc (NASDAQ:VTAE)
Biotechnology Value Fund L P filed with SEC a SC 13G/Aform about Vitae Pharmaceuticals, Inc. The form can be accessed here: 000092189515002173. As reported by Biotechnology Value Fund L P, the filler increased its stake in the stock by 35.56% for 2,375,933 shares. Biotechnology Value Fund L P currently owns 10.9% of the stock. This ownership filing was filed because activity on September 28, 2015.
Vitae Pharmaceuticals, Inc Institutional Sentiment
Latest Security and Exchange filings show 49 investors own Vitae Pharmaceuticals, Inc. The institutional ownership in Q1 2015 is low, at 53.72% of the outstanding shares. This is increased by 4498308 the total institutional shares. 11737773 were the shares owned by these institutional investors. In total 26 funds opened new Vitae Pharmaceuticals, Inc stakes, 15 increased stakes. There were 9 that closed positions and 5 reduced them.
Wellcome Trust Ltd is an institutional investor bullish on Vitae Pharmaceuticals, Inc, owning 423001 shares as of Q1 2015 for 0.11% of its portfolio. Travelers Companies Inc owns 4057 shares or 0.01% of its portfolio. MD Nea Management Company Llc have 1.38% of their stock portfolio for 2613199 shares. Further, Awm Investment Company Inc reported stake worth 1.41% of its US stock portfolio. The CA Bvf Inc owns 1577435 shares. Vitae Pharmaceuticals, Inc is 3.86% of the manager’s US portfolio.
Business Profile
Vitae Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform. The Company has two partnered product candidates in the clinic and several wholly owned drug candidates in preclinical development. The Company’s two partnered product candidates are VTP-34072, which is in a Phase II clinical trial for the treatment of type 2 diabetes, and BI 1147560 for the treatment and prevention of Alzheimer’s disease. The Company’s several wholly owned product candidates advancing in preclinical development, including VTP-43742 for the treatment of autoimmune disorders, VTP-38543 for the treatment of atopic dermatitis and VTP-38443 for the treatment of acute coronary syndrome.
SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.
